Resveratrol Does Not Influence Metabolic Risk Markers Related to Cardiovascular Health in Overweight and Slightly Obese Subjects: A Randomized, Placebo-Controlled Crossover Trial
Open accessAbstract
BACKGROUND: In vitro and animal studies have shown positive effects of resveratrol on lipid and lipoprotein metabolism, but human studies specifically designed to examine these effects are lacking. OBJECTIVE: The primary outcome parameter of this study in overweight and slightly obese subjects was the effect of resveratrol on apoA-I concentrations. Secondary outcome parameters were effects on other markers of lipid and lipoprotein metabolism, glucose metabolism, and markers for inflammation and endothelial function. DESIGN: This randomized, placebo-controlled crossover study was conducted in 45 overweight and slightly obese men (n = 25) and women (n = 20) with a mean age of 61 ± 7 years. Subjects received in random order resveratrol (150 mg per day) or placebo capsules for 4 weeks, separated by a 4-week wash-out period. Fasting blood samples were collected at baseline and at the end of each intervention period. RESULTS: Compliance was excellent as indicated by capsule count and changes in resveratrol and dihydroresveratrol concentrations. No difference between resveratrol and placebo was found in any of the fasting serum or plasma metabolic risk markers (mean ± SD for differences between day 28 values of resveratrol vs. placebo: apoA-I; 0.00 ± 0.12 g/L (P = 0.791), apoB100; -0.01 ± 0.11 g/L (P = 0.545), HDL cholesterol; 0.00 ± 0.09 mmol/L (P = 0.721), LDL cholesterol -0.03 ± 0.57 mmol/L (P = 0.718), triacylglycerol; 0.10 ± 0.54 mmol/L (P = 0.687), glucose; -0.08 ± 0.28 mmol/L (P = 0.064), insulin; -0.3 ± 2.5 mU/L (P = 0.516)). Also, no effects on plasma markers for inflammation and endothelial function were observed. No adverse events related to resveratrol intake were observed. CONCLUSION: 150 mg of daily resveratrol intake for 4 weeks does not change metabolic risk markers related to cardiovascular health in overweight and slightly obese men and women. Effects on glucose metabolism warrant further study. TRIAL REGISTRATION: ClinicalTrials.gov NCT01364961.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In van der Made et al.'s trial, resveratrol 150 mg once daily for 4 weeks in overweight/obese patients with type 2 diabetes produced no change in metabolic parameters (fasting glucose, insulin, lipid profile), inflammation markers, or endothelial function (IL-6, TNFα, sVCAM-1, sICAM-1).
“No change in metabolic parameters (fasting glucose, insulin, and lipid profile), inflammation markers, and endothelial function i.e., interleukin-6 (IL-6), tumor necrosis factor α (TNF α), soluble vascular adhesion molecule-1 (sVCAM-1), and soluble intracellular adhesion molecule-1 (sICAM-1) was observed.”
From The Role of Resveratrol Administration in Human Obesity (2021) · cites this paper as [37]
In van der Made et al.'s trial, resveratrol was well tolerated and no adverse reactions were reported.
“Resveratrol was well tolerated and no adverse reactions were reported [37].”
From The Role of Resveratrol Administration in Human Obesity (2021) · cites this paper as [37]
In van der Made et al.'s trial, alkaline phosphatase (ALP) increased significantly after resveratrol administration.
“they found that alkaline phosphatase (ALP) increased significantly after administration of resveratrol.”
From The Role of Resveratrol Administration in Human Obesity (2021) · cites this paper as [37]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423 · see citing works
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502 · see citing works
Toprak, Ö., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney & Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,769 · see citing works
Antihyperlipidemic and Biochemical Activities of Mcy Protein in Streptozotocin Induced Diabetic Rats
Marella, S., Maddirela, D. R., Badri, K. R., Kumar, M. V. J., & Chippada, A. R. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373954 · Cited by 5,938 · see citing works
High density lipoprotein as a protective factor against coronary heart disease
Gordon, T., Castelli, W. P., Hjortland, M. C., Kannel, W. B., & Dawber, T. R. (1977) · The American Journal of Medicine · doi:10.1016/0002-9343(77)90874-9 · Cited by 5,059 · see citing works
Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study
Hertog, M. G. L., Feskens, E. J. M., Kromhout, D., Hertog, M. G. L., Hollman, P. C. H., Hertog, M. G. L., & Katan, M. (1993) · The Lancet · doi:10.1016/0140-6736(93)92876-u · Cited by 4,336 · see citing works
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139 · see citing works
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911 · see citing works
Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study
Castelli, W. P. (1986) · JAMA · doi:10.1001/jama.256.20.2835 · Cited by 2,305 · see citing works
Effects of dalcetrapib in patients with a recent acute coronary syndrome
Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022 · see citing works
Incidence of Coronary Heart Disease and Lipoprotein Cholesterol Levels
Castelli, W. P. (1986) · JAMA · doi:10.1001/jama.1986.03380200073024 · Cited by 1,620 · see citing works
Timmers, S., Konings, E., Bilet, L., Houtkooper, R. H., van de Weijer, T., Goossens, G. H., Hoeks, J., van der Krieken, S., Ryu, D., Kersten, S., et al. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.10.002 · Cited by 1,320 · see citing works
Sharrett, A. R., Ballantyne, C. M., Coady, S., HEISS, G. M., Sorlie, P. D., Catellier, D., & Patsch, W. (2001) · Circulation · doi:10.1161/hc3501.095214 · Cited by 942 · see citing works
Assmann, G., Schulte, H., von Eckardstein, A., & Huang, Y. (1996) · Atherosclerosis · doi:10.1016/0021-9150(96)05852-2 · Cited by 693 · see citing works
Brasnyó, P., Molnár, G. A., Mohás, M., Markó, L., Laczy, B., Cseh, J., Mikolás, E., Szijártó, I. A., Mérei, Á., Halmai, R., et al. (2011) · British Journal Of Nutrition · doi:10.1017/s0007114511000316 · Cited by 680 · see citing works
Polyphenols and prevention of cardiovascular diseases
Manach, C., Mazur, A., & Scalbert, A. (2005) · Current Opinion in Lipidology · doi:10.1097/00041433-200502000-00013 · Cited by 680 · see citing works
Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus
Bhatt, J. K., Thomas, S., & Nanjan, M. J. (2012) · Nutrition Research · doi:10.1016/j.nutres.2012.06.003 · Cited by 475 · see citing works
High-Dose Resveratrol Supplementation in Obese Men
Poulsen, M. M., Vestergaard, P. F., Clasen, B. F., Radko, Y., Christensen, L. P., Stødkilde-Jørgensen, H., Møller, N., Jessen, N., Pedersen, S. B., & Jørgensen, J. O. L. (2013) · Diabetes · doi:10.2337/db12-0975 · Cited by 455 · see citing works
Favorable effects of berry consumption on platelet function, blood pressure, and HDL cholesterol
Erlund, I., Koli, R., Alfthan, G., Marniemi, J., Puukka, P., Mustonen, P., Mattila, P., & Jula, A. (2008) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/87.2.323 · Cited by 445 · see citing works
In vivo and in vitro metabolism of trans-resveratrol by human gut microbiota
Bode, L. M., Bunzel, D., Huch, M., Cho, G., Ruhland, D., Bunzel, M., Bub, A., Franz, C. M. A. P., & Kulling, S. E. (2013) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.112.049379 · Cited by 398 · see citing works
Yoshino, J., Conte, C., Fontana, L., Mittendorfer, B., Imai, S., Schechtman, K. B., Gu, C. C., Kunz, I., Fanelli, F. R., Patterson, B. W., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.09.015 · Cited by 381 · see citing works
Csiszár, A., Smith, K. E., Labinskyy, N., Orosz, Z. Z., Rivera, A., & Ungvari, Z. I. (2006) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00340.2006 · Cited by 274 · see citing works
Inoue, H., Jiang, X., Katayama, T., Osada, S., Umesono, K., & Namura, S. (2003) · Neuroscience Letters · doi:10.1016/j.neulet.2003.09.001 · Cited by 232 · see citing works
Boekholdt, S. M., Arsenault, B. J., Hovingh, G. K., Mora, S., Pedersen, T. R., LaRosa, J. C., Welch, K. M. A., Amarenco, P., DeMicco, D. A., Tonkin, A. M., et al. (2013) · Circulation · doi:10.1161/circulationaha.113.002670 · Cited by 196 · see citing works
Sahebkar, A. (2013) · Nutrition Reviews · doi:10.1111/nure.12081 · Cited by 192 · see citing works
Chronic resveratrol consumption improves brachial flow-mediated dilatation in healthy obese adults
Wong, R. H. X., Berry, N. M., Coates, A. M., Buckley, J. D., Bryan, J., Kunz, I., & Howe, P. R. C. (2013) · Journal of Hypertension · doi:10.1097/hjh.0b013e328362b9d6 · Cited by 162 · see citing works
Sacanella, E., Vázquez-Agell, M., Mena, M.-P., Antúnez, E., Fernández‐Solà, J., Nicolas, J. M., Lamuela-Raventós, R. M., Ros, E., & Estruch, R. (2007) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/86.5.1463 · Cited by 138 · see citing works
Agarwal, B., Campen, M. J., Channell, M. M., Wherry, S. J., Varamini, B., Davis, J. G., Baur, J. A., & Smoliga, J. M. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.09.027 · Cited by 137 · see citing works
Beneficial Effects of Resveratrol on Atherosclerosis
Fan, E., Zhang, L., Jiang, S., & Bai, Y. (2008) · Journal of Medicinal Food · doi:10.1089/jmf.2007.0091 · Cited by 106 · see citing works
Dash, S., Xiao, C., Morgantini, C., Szeto, L., & Lewis, G. F. (2013) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.113.302342 · Cited by 102 · see citing works
Csiszár, A., Smith, K. E., Labinskyy, N., Orosz, Z. Z., Rivera, A., & Ungvari, Z. I. (2007) · The FASEB Journal · doi:10.1096/fasebj.21.5.a450-a · Cited by 84 · see citing works
The dietary antioxidant resveratrol affects redox changes of PPARα activity
Iannelli, P., Zarrilli, V., Varricchio, E., et al. (2006) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2005.12.011 · Cited by 30 · see citing works
Apolipoprotein A-I mimetic peptides
Hovingh, G. K., Bochem, A. E., & Kastelein, J. J. P. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283404507 · Cited by 28 · see citing works
Stilbene analogs as inducers of apolipoprotein-I transcription
Hansen, H. C., Chiacchia, F. S., Patel, R. G., et al. (2010) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2009.12.076 · Cited by 15 · see citing works
Nicholls, S. J. (2011) · Current Cardiology Reports · doi:10.1007/s11886-011-0223-0 · Cited by 5 · see citing works
Vázquez-Agell, M., Estruch, R., Sacanella, E., et al. (2007) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(07)71283-7 · Cited by 3 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Western Diet and the Immune System: An Inflammatory Connection
Christ, A., Lauterbach, M., & Latz, E. (2019) · Immunity · doi:10.1016/j.immuni.2019.09.020 · Cited by 907 · see citing works
Health benefits of resveratrol: Evidence from clinical studies
Singh, A. P., Singh, R., Verma, S. S., Rai, V., Kaschula, C. H., Maiti, P., & Gupta, S. C. (2019) · Medicinal Research Reviews · doi:10.1002/med.21565 · Cited by 523 · see citing works
Guasch-Ferré, M., Merino, J., Sun, Q., Fitó, M., & Salas-Salvadó, J. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/6723931 · Cited by 297 · see citing works
Bo, S., Ponzo, V., Ciccone, G., Evangelista, A., Saba, F., Goitre, I., Procopio, M., Pagano, G. F., Cassader, M., & Gambino, R. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.08.010 · Cited by 146 · see citing works
Cardiovascular and antiobesity effects of resveratrol mediated through the gut microbiota
Bird, J. K., Raederstorff, D., Weber, P., & Steinert, R. E. (2017) · Advances in Nutrition · doi:10.3945/an.117.016568 · Cited by 136 · see citing works
de Ligt, M., Bruls, Y. M. H., Hansen, J., Habets, M.-F., Havekes, B., Nascimento, E. B. M., Moonen-Kornips, E., Schaart, G., Schrauwen-Hinderling, V. B., van Marken Lichtenbelt, W., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.04.004 · Cited by 79 · see citing works
The Role of Resveratrol Administration in Human Obesity
Mongioì, L. M., La Vignera, S., Cannarella, R., Cimino, L., Compagnone, M., Condorelli, R. A., & Calogero, A. E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094362 · Cited by 71 · see citing works
- Authors
- van der Made, S. M., Plat, J., & Mensink, R. P.
- Affiliations
- Maastricht University Medical Centre (NL)
- Corresponding author
- Mensink, Ronald P.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-03-19
- Volume
- 10
- Issue
- 3
- Pages
- e0118393
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4366169
- OpenAlex
- W2094139493
- Cited by
- 131
- References
- 36
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 8 · 2023: 7 · 2022: 12 · 2021: 21 · 2020: 16 · 2019: 12 · 2018: 16 · 2017: 12 · 2016: 14 · 2015: 2
- FWCI
- 7.32
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Funders
- DSM Nutritional Products
- Topics
- Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
- Health Sciences › Medicine › Biochemistry › Phytochemicals and Antioxidant Activities
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- resveratrol, overweight, mild obesity, metabolic risk markers, cardiovascular health, apolipoprotein A-I, apolipoprotein B-100, HDL cholesterol, LDL cholesterol, triglycerides, glucose metabolism, insulin, inflammation, endothelial function, lipid metabolism, older adults, dietary supplementation, compliance, adverse events
- MeSH terms
- Resveratrol, Aged, Cardiovascular Diseases, Female, Humans, Lipoproteins, Male, Middle Aged, Obesity, Stilbenes, Biomarkers, Apolipoprotein A-I, Cross-Over Studies, Overweight, Lipid Metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
